Lsm7 Related Leukodystrophy And Cerebellar Atrophy C6012719
LSM7-related leukodystrophy is a rare genetic disorder that affects the brain's white matter and cerebellum. It causes progressive neurological decline, including movement problems and loss of brain function. There is currently no cure, and treatment focuses on managing symptoms and supportive care.
Key facts at a glance
- ICD-10
- G40.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Optic neuropathy
Cerebellar ataxia
(neurologic)Generalized symptoms
(neurologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Spasticity
(neurologic)Peripheral neuropathy
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
Neurological monitoring and imaging
Regular MRI scans and neurological assessments to track disease progression and inform treatment decisions. Includes periodic evaluation of motor function, cognitive abilities, and cerebellar symptoms.
Physical and occupational therapy
Individualized therapy programs focusing on balance, coordination, gait training, and fine motor skills. Therapy helps maintain function and may slow deterioration through targeted exercises.
Additional treatment options
Symptomatic pharmacological management
Medications addressing specific symptoms such as spasticity, tremor, seizures, or sleep disturbances. Treatment selection is based on individual symptom presentation.
medicationNeuropsychological support and counseling
Psychological services addressing cognitive changes, emotional adjustment, and family counseling for chronic neurological conditions. Includes cognitive rehabilitation strategies.
psychologicalMultidisciplinary supportive care
Coordinated care involving neurology, genetics, rehabilitation, and supportive services. Focuses on quality of life optimization and comprehensive disease management.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Lsm7 Related Leukodystrophy And Cerebellar Atrophy C6012719?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Lsm7 Related Leukodystrophy And Cerebellar Atrophy C6012719. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy